Phase 3 Readout

REPL: Phase 3 Topline: Phase 3 Study to Evaluate the Safety and Efficacy of AAV5-hRKp.RPGR for the Treatment of Japanese X-

Name: Phase 3 Topline: Phase 3 Study to Evaluate the Safety and Efficacy of AAV5-hRKp.RPGR for the Treatment of Japanese X-
Start: 2030-11-12
End: 2030-11-12

November 12, 2030. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: November 12, 2030
Company: Replimune Group, Inc. (REPL)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: Phase 3 Study to Evaluate the Safety and Efficacy of AAV5-hRKp.RPGR for the Treatment of Japanese X-

November 12, 2030

REPL overview →

Company: Replimune Group, Inc. (REPL)
Indication: Retinitis Pigmentosa